A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer
Clinical trial NCT06686576 · RECRUITING
Trial details
- NCT number
- NCT06686576
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-12
- Primary completion
- 2030-12-01
- Enrollment
- 363
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.